AGF94

AGF94 is a novel 6-substituted pyrrolo[2,3-d]pyrimidine antifolate designed for the targeted treatment of epithelial ovarian cancer (EOC). It functions as a potent inhibitor of de novo purine nucleotide biosynthesis, a critical pathway for DNA and RNA synthesis in rapidly dividing cancer cells. AGF94 is uniquely engineered for selective cellular uptake through three distinct transport systems: the folate receptor alpha (FRα), which is overexpressed in most EOCs; the proton-coupled folate transporter (PCFT); and the folate receptor beta (FRβ), which is expressed on activated M2-like macrophages. This multi-targeted transport mechanism allows AGF94 to not only exert direct cytotoxic effects on tumor cells but also to modulate the tumor microenvironment by depleting immunosuppressive macrophages and promoting T-cell infiltration. Preclinical studies in syngeneic mouse models of high-grade serous ovarian cancer have demonstrated significant anti-tumor efficacy and immune-modulatory potential.

Other names

FLAG 094FLAG094FLAG-094